Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives

Marco Gallo, Pasqualino Malandrino, Giuseppe Fanciulli, Francesca Rota, Antongiulio Faggiano, Annamaria Colao, Manuela Albertelli, Vito Amoroso, Emanuela Arvat, Giuseppe Badalamenti, Emilio Bajetta, Roberto Baldelli, Antonio Bianchi, Roberto Buzzoni, Davide Campana, Carlo Carnaghi, Giacomo Cartenì, Sara Cingarlini, Vittorio Colantuoni, Jorgelina CoppaFrancesco Corcione, Maria Vittoria Davı´, Gaetano De Rosa, Ettore C. Degli Uberti, Marialaura Del Basso de Caro, Antonella Di Sarno, Massimo Falconi, Piero Ferolla, Diego Ferone, Germano Gaudenzi, Carla Giordano, Dario Giuffrida, Erika Maria Grossrubatscher, Elia Guadagno, Valentina Guarnotta, Andrea Lania, Silvana Leo, Fabio Lo Calzo, Francesco Logoluso, Marco Manzoni, Massimo Marchetti, Chiara Martini, Erika Messina, Massimo Milione, On Behalf Of Nike Group

Research output: Contribution to journalArticle

Abstract

Purpose: Everolimus has been shown to be effective for advanced pancreatic neuroendocrine tumours (pNETs), but its positioning in the therapeutic algorithm for pNETs is matter of debate. Methods: With the aim to shed light on this point, we performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies, and the recommendations of international guidelines. In addition, we performed an extensive search on the Clinical Trial Registries databases worldwide, to gather information on the ongoing clinical trials related to this specific topic. Results: We identified eight retrospective published studies, two prospective published studies, and five registered clinical trials. Moreover, we analyzed the content of four widespread international guidelines. Conclusions: Our critical review confirms the lack of high-quality data to recommend everolimus as the first line therapy for pNETs. The ongoing clinical trials reported in this review will hopefully help clinicians, in the near future, to better evaluate the role of everolimus as the first line therapy for pNETs. However, at the moment, there is already enough evidence to recommend everolimus as the first line therapy for patients with symptomatic malignant unresectable insulin-secreting pNETs, to control the endocrine syndrome regardless of tumour growth.

Original languageEnglish
Pages (from-to)1-16
Number of pages16
JournalJournal of Cancer Research and Clinical Oncology
DOIs
Publication statusPublished - Jul 2017

Keywords

  • Everolimus
  • mTOR inhibitors
  • Neuroendocrine tumours
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives'. Together they form a unique fingerprint.

  • Cite this

    Gallo, M., Malandrino, P., Fanciulli, G., Rota, F., Faggiano, A., Colao, A., Albertelli, M., Amoroso, V., Arvat, E., Badalamenti, G., Bajetta, E., Baldelli, R., Bianchi, A., Buzzoni, R., Campana, D., Carnaghi, C., Cartenì, G., Cingarlini, S., Colantuoni, V., ... On Behalf Of Nike Group (2017). Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. Journal of Cancer Research and Clinical Oncology, 1-16. https://doi.org/10.1007/s00432-017-2407-5